<DOC>
	<DOCNO>NCT00391768</DOCNO>
	<brief_summary>The purpose study learn treat influenza child le 2 year age . Tamiflu速 , drug study , approve treatment child 1 year age old influenza . Researchers want learn activity Tamiflu速 body determine dose safe , well-tolerated , effective young child influenza . Children le 24 month age confirm influenza receive Tamiflu速 2 time day 5 day . Older participant enrol first young child enrol safety data review old participant . Study procedure include blood sample , swab inside nose , body nervous system evaluation . Participants may involve study related procedure 37 day .</brief_summary>
	<brief_title>Oseltamivir Treatment Children Less Than 24 Months Age With Influenza</brief_title>
	<detailed_description>Oseltamivir approve prophylaxis treatment child 1 year age old influenza . Influenza treatments child age 1 year need mortality influenza high among age group , even underlie medical condition . Oseltamivir frequently use off-label child less 1 year age , data support dos use . Given risk severe fatal influenza infection infant , lack repeat dose pharmacokinetic ( PK ) data child less 2 , need treatment population child , fact oseltamivir use off-label population , current study systematically study PK safety oseltamivir child less 2 year age confirm influenza determine appropriate dose use age group . This data critical pediatrician care potentially gravely ill infant . This study prospective , age-stratified PK/pharmacodynamic ( PD ) safety evaluation oseltamivir therapy child less 24 month age confirm influenza infection . Participants stratify age follow enrollment scheme study initiation : 12-23 month ( Cohort I ) , 9-11 month ( Cohort II ) , 6-8 month ( Cohort III ) , 3-5 month ( Cohort IV ) 0-2 month ( Cohort V ) . At study onset , Cohort II III enrol simultaneously . Cohorts IV V enrol sequentially decrease age group predicate upon PK safety data precede cohort . In event public health emergency , Data Safety Monitoring Board ( DSMB ) Food Drug Administration ( FDA ) may authorize follow modification propose enrollment plan : opening young age cohort without full dataset next high age cohort , re-opening previously close cohort obtain additional data and/or over-enrollment 5 cohort . The old cohort ( Cohort I ) may enrol time study . The primary study objective define PK oseltamivir oseltamivir carboxylate child confirm influenza le 2 year age . The oseltamivir dose initially evaluate Cohort I approve dose 30 mg twice day ( bid ) . However , oseltamivir carboxylate area curve ( AUC ) 12 value 5 9 subject enrol Cohort I August 5 , 2009 , low range utilized cohort study , GM AUC12 Cohort I group [ ( 2589 nanogram per hour per milliliter ( ngxh/mL ) ] . As consequence , DSMB recommend August 5 , 2009 , protocol amend utilize weight-based dose oseltamivir subject subsequently enrol Cohort I , employ target AUC approach use Cohorts II-V cohort well . Based upon PK data available date , initial weight-based dose evaluate Cohort I 3.5 mg/kg bid . A dose oseltamivir 3 mg/kg/dose orally bid 5 day ( 10 dos ) administer first 9 subject Cohorts II-III . Additional subject may enrol target AUC12 range achieve . The propose dose subject enrol Cohorts IV V 3 mg/kg/dose orally bid 5 day ( 10 dos ) , although dose may adjust prior open Cohort IV V base dose require achieve target oseltamivir carboxylate AUC12 range previous cohort .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Signed informed consent parent ( ) legal guardian ( ) . Age : Cohort I : 12 23 mo . Cohort II : 9 11 mo . Cohort III : 6 8 mo . Cohort IV : 3 5 mo . Cohort V : 0 2 mo . Confirmed laboratory diagnosis influenza viral culture rapid influenza diagnostic test within 96 hour prior study enrollment . Duration influenza symptom less equal 96 hour . Concomitant vomit illness would preclude ability take drug . Immunocompromised subject ( e.g. , malignancy , congenital agammaglobulinemia , HIV ) . Documented renal impairment ( e.g. , polycystic renal disease , nephrectomy , renal transplantation , renal agenesis , dialysis requirement , renal failure , nephrotic syndrome time prior enrollment , current receipt diuretic therapy ) . Documented hepatic impairment ( e.g. , congenital hepatitis , biliary atresia , cholelithiasis ) . Gastrointestinal abnormality might hinder absorption oral medication . Current receipt inotropic drug ( e.g. , epinephrine , norepinephrine , dopamine , dobutamine ) . History seizure . Documented congenital malformation central nervous system define birth ( e.g. , hydranencephaly , prosencephaly , spina bifida ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>influenza , oseltamivir , Tamiflu速 , antiviral , child , infant</keyword>
</DOC>